Atrium Therapeutics, Inc.
RNA
Positions held
Your positionsRNA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $141.29M | Enterprise value | -$120.92M | Trailing P/E | — | Forward P/E | -1.02 |
| PEG | — | Price / book | 0.66 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | -21.9% | Earnings growth | — | Gross margin | -56.4% | Operating margin | -7.5% |
| Profit margin | -1.8% | ROE | — | ROA | — | Debt / equity | 0.01 |
| Current ratio | 8.73 | Free cash flow | — | Analyst recommendation | none | Mean target | $25.00 |
| 52w high | $16.77 | 52w low | $7.63 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $19.6M | $0.9M | $12.3M | $3.8M | — |
| Op margin | -752.9% | -88.0% | -5592.0% | -68.6% | -334.4% | — |
| Net income | -$20.2M | -$16.6M | -$48.1M | -$8.3M | -$12.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.6M | -$17.3M | -$48.0M | -$8.5M | -$12.9M | — |
- Revenue -85% vs prior quarter ($3.0M vs $20M).
- Operating margin compressed to -752.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $18.6M | $10.9M | $9.8M |
| Op margin | -412.6% | -121.3% | -65.4% |
| Net income | -$76.7M | -$25.1M | -$6.4M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$76.8M | -$13.2M | -$6.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Atrium Therapeutics Announces $50 Million Private Placement
2026-09-21 · Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-06 · Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
2026-09-02 · Atrium Therapeutics to Participate in Upcoming Investor Conferences
2026-08-28 · Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
2026-08-20 · Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13 · Atrium Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-13 · Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb
2026-08-06 · Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
2026-07-20 · Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-14 · Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
Price (daily)
Full chart · RSI · MACD · patterns